Loading clinical trials...
Loading clinical trials...
Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Herlev Hospital
NCT05227547 · Chronic Obstructive Lung Disease, Chronic Obstructive Pulmonary Disease
NCT07015216 · Chronic Obstructive Lung Disease
NCT06629675 · Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Lung Disease, and more
NCT07425210 · Chronic Obstructive Lung Disease (COLD)
NCT05838911 · Pulmonary Rehabilitation, Chronic Obstructive Lung Disease, and more
Herlev University Hospital
Herlev
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions